| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | RVP1; HRVP1; C7orf1; CPE-R2; CPETR2 |
| Entrez GeneID | 1365 |
| WB Predicted band size | Calculated MW: 23 kDa; Observed MW: 20 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human Claudin 3 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于Claudin 3抗体的3篇参考文献及其摘要内容：
1. **文献名称**：*"Claudin-3 and Claudin-4: Differential Activation by Epigenetic Treatment in Ovarian Cancer"*
**作者**：Hübner et al.
**摘要**：该研究探讨了表观遗传药物(如DNA甲基化抑制剂)对卵巢癌细胞中Claudin 3和Claudin 4表达的调控作用，发现Claudin 3抗体在免疫组化中可有效检测其表达上调，提示其在表观治疗中的潜在应用价值。
2. **文献名称**：*"Claudin-3 as a Marker for Claudin-Low Subtype in Breast Cancer"*
**作者**：Prat et al.
**摘要**：通过免疫印迹和免疫荧光技术，研究利用Claudin 3抗体鉴定乳腺癌中的Claudin-low亚型，发现其低表达与肿瘤干细胞特性及不良预后相关，为分子分型提供依据。
3. **文献名称**：*"Targeting Claudin-3 in Prostate Cancer with a Monoclonal Antibody"*
**作者**：Liu et al.
**摘要**：开发了一种靶向Claudin 3的单克隆抗体，并在前列腺癌模型中验证其抗肿瘤活性。实验显示，该抗体通过抑制Wnt/β-catenin通路减少肿瘤生长和转移，提示其治疗潜力。
4. **文献名称**：*"Claudin-3 Expression in Colorectal Cancer: A Tissue Microarray Study"*
**作者**：Dhawan et al.
**摘要**：利用组织芯片技术和Claudin 3抗体分析结直肠癌组织中蛋白的表达模式，发现Claudin 3高表达与淋巴结转移和晚期分期显著相关，可能作为预后标志物。
这些文献涵盖了Claudin 3抗体在癌症诊断、分型和靶向治疗中的应用，涉及卵巢癌、乳腺癌、前列腺癌及结直肠癌等多种肿瘤类型。
Claudin 3 is a member of the claudin family, a group of transmembrane proteins critical for forming tight junctions—specialized cell-cell adhesion structures that regulate paracellular permeability and maintain cell polarity. As a key component of epithelial and endothelial barriers, Claudin 3 contributes to controlling the movement of ions and molecules across tissues. Structurally, it contains four transmembrane domains and two extracellular loops, which mediate homotypic or heterotypic interactions with other claudins. Dysregulation of Claudin 3 expression is linked to various pathologies, including cancer, where its overexpression has been observed in malignancies such as breast, ovarian, prostate, and gastrointestinal cancers, often correlating with metastasis and poor prognosis. It also plays a role in viral entry, notably facilitating hepatitis C virus infection.
Claudin 3 antibodies are widely used as research tools to study tight junction dynamics, tissue integrity, and disease mechanisms. In diagnostics, these antibodies aid in detecting Claudin 3 expression patterns in tumors, serving as potential biomarkers for cancer identification or therapeutic targeting. Therapeutically, Claudin 3 is explored for antibody-based treatments, though challenges like tumor specificity and off-target effects remain. Its dual role in barrier function and disease underscores its biological and clinical significance.
×
